Novo Nordisk remains financially strong, but pricing pressures and CagriSema challenges limit near-term upside. Find out why ...

and glucose-dependent insulinotropic polypeptide (GIP) receptors -- achieved promising results in a Phase 2 study, demonstrating sustained weight loss in patients with obesity. Its novel dual ...

Q2 2025 Results Conference Call May 8, 2025 8:00 AM ETCompany ParticipantsSam Fisch - Executive Director, Investor Relations ...

You can even pick up athlete’s foot from bed sheets or clothes that have ... infection Are not able to walk Can’t put weight on your foot Have diabetes and a wound that’s either not getting ...

Glucose tracking is a natural part of Oura’s $75 million investment from Dexcom.

Eli Lilly has seen positive results from a phase 3 trial of Orforglipron, the first-ever GLP-1 pill for weight loss and type ...

Oura Ring is the best smart ring on the market (according to Mashable's tests, at least), and its holistic approach to health ...

Researchers found that by December 2023, more than 1 in 3 of the medications being started for type 2 diabetes treatment were GLP-1RA-based medications. When it comes to managing weight loss and ...

This was found in research funded by Eli Lilly, the manufacturer of the diabetes and weight loss drugs Mounjaro® and Zepbound®. What does semaglutide do to your body? In real-life terms ...

because your blood sugar, insulin, and medications will need special attention while you're losing weight. You don’t need to lose that much to make a difference for your health. One study found ...

He added, "Overall, we are saving the healthcare system money, so I would like to see Medicare and Medicaid approve them for diabetes and weight loss." Dr. Brett Osborn, a Florida neurologist and ...